Literature DB >> 8294094

Augmentation of portal blood flow improves function of human cirrhotic liver.

J E Cardoso1, C Gautreau, P R Jeyaraj, D Patrzalek, B Cherruau, M Vaubourdolle, C Legendre, T Wroblewski, D Houssin.   

Abstract

In cirrhotic livers, the intrahepatic resistance is increased and drug elimination and portal transhepatic flow are decreased. The aim of our work was to study the effect of a twofold increase in portal blood flow during 2 hr on the hemodynamic parameters, drug elimination and hepatic viability in eight isolated perfused human cirrhotic livers. Using an oxygenated recirculating system with independent arterial and portal flows, we perfused livers with Kreb's buffer bicarbonate solution, bovine serum albumin (20 gm.L-1) and human red blood cells (hematocrit 20%). The flow was maintained at a basal level of 0.713 +/- 0.19 L/min for 1 hr and then increased and maintained for 2 hr at twice the basal flow. Portal pressure-portal flow curve slopes were linear (27.04 +/- 21.06 mm Hg.L-1 x min; range = 6.43 to 60.8) and correlated with intrahepatic resistance during the basal-flow period (r = 0.87, p < 0.01). Parameters registered during the basal- and high-flow periods were compared by use of Student's t test: portal pressure increased from 23.5 +/- 7 to 37.3 +/- 16.7 mm Hg (p < 0.05); arterial pressure increased from 80.3 +/- 19 to 103.5 +/- 26 mm Hg (p < 0.005); hepatic artery flow resistance increased 31.9% (from 690.1 +/- 218 to 899.4 +/- 269 mm Hg.L-1 x min; p < 0.005); indocyanine green clearance increased by 28.2% (from 86.0 +/- 58.3 to 109.2 +/- 74.8 ml.min-1 x kg liver-1; p < 0.04). No significant differences were observed in enzyme release, biliary flow (n = 5) and oxygen consumption. Histological examinations demonstrated sinusoidal dilatations in six of eight cases.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8294094

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  6 in total

Review 1.  Treatment and management of ascites and hepatorenal syndrome: an update.

Authors:  Kurt Lenz; Robert Buder; Lisbeth Kapun; Martin Voglmayr
Journal:  Therap Adv Gastroenterol       Date:  2015-03       Impact factor: 4.409

2.  Balloon-occluded retrograde transvenous obliteration for gastric variceal bleeding: its feasibility compared with transjugular intrahepatic portosystemic shunt.

Authors:  Young Ho Choi; Chang Jin Yoon; Jae Hyung Park; Jin Wook Chung; Jong Won Kwon; Guk Myung Choi
Journal:  Korean J Radiol       Date:  2003 Apr-Jun       Impact factor: 3.500

Review 3.  Successful balloon-occluded retrograde transvenous obliteration for ruptured gastric fundal varices in a patient with Child-Pugh C cirrhosis: case report and literature review.

Authors:  Yasuji Komorizono; Katsumi Sako; Yoriko Kajiya; Kiyohisa Kamimura; Niihara Tooru; Hiroto Nishimata; Kouichirou Shigeta; Kunio Fujisaki
Journal:  Dig Dis Sci       Date:  2004-02       Impact factor: 3.199

4.  Balloon-occluded Retrograde Transvenous Obliteration (BRTO): Follow-Up and Postprocedural Imaging.

Authors:  Brian G Sauer; Saher S Sabri; Vanessa M Shami; Abdullah M S Al-Osaimi
Journal:  Semin Intervent Radiol       Date:  2011-09       Impact factor: 1.513

5.  Balloon-occluded Retrograde Transvenous Obliteration (BRTO): Preprocedural Evaluation and Imaging.

Authors:  Abdullah M S Al-Osaimi; Saher S Sabri; Stephen H Caldwell
Journal:  Semin Intervent Radiol       Date:  2011-09       Impact factor: 1.513

6.  The short-term effects of balloon-occluded retrograde transvenous obliteration, for treating gastric variceal bleeding, on portal hypertensive changes: a CT evaluation.

Authors:  Sung Ki Cho; Sung Wook Shin; Eun Young Yoo; Young Soo Do; Kwang Bo Park; Sung Wook Choo; Heon Han; In Wook Choo
Journal:  Korean J Radiol       Date:  2007 Nov-Dec       Impact factor: 3.500

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.